anti-HIV antibodies

anti-HIV antibodies

antibodies formed a few weeks after exposure to human immunodeficiency virus (HIV); the person has seroconverted, and is termed 'HIV-positive'
Mentioned in ?
References in periodicals archive ?
The US study detected anti-HIV antibodies by enzyme-linked immunosorbent assay (ELISA) testing in 14% of uninfected infants > 18 months of age, with the median time to seroreversion occurring at > 13 months of age.
Advances in isolating antibodies from HIV-infected individuals have allowed for the discovery of a large number of new, broadly neutralizing anti-HIV antibodies directed against the host receptor (CD4) binding site--a functional site at the surface of the virus that allows for cell entry and infection.
Current advances in isolating antibodies from HIV-infected individuals have allowed for the discovery of a large number of new, broadly neutralizing anti-HIV antibodies directed against the host receptor (CD4) binding site -- a functional site on the surface of the virus that allows for cell entry and infection.
Researchers at Rockefeller University and colleagues have now made two fundamental discoveries about the so-called broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay.
In the US, the presence of anti-HIV antibodies in the blood of someone who has the constellation of symptoms of AIDS, such as diarrhea, dementia, Kaposi's sarcoma, pneumonia, and tuberculosis, would be determined to have AIDS.
Their white blood cells flood the body with anti-HIV antibodies, although how this process works is still unclear.
Tokyo, Japan, July 19, 2006 - (JCN) - Trans Genic, a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046.
When a minuscule blood sample spreads through the channels, any anti-HIV antibodies in the blood will stick to the stripe.
HIV infection is routinely diagnosed by various immunoassays that detect the presence of anti-HIV antibodies in body fluids (blood, saliva or urine).
The result is a constantly evolving population of HIV and anti-HIV antibodies in which the virus inevitably outpaces the antibodies, until the virus eventually depletes the body's immune response (or virus fighting cells).
The focus of the grant is to develop more effective anti-HIV antibodies based on Profectus Biosciences' proprietary Antiviral Immune Modulation (AIM) therapy technology, in collaboration with the Institute of Human Virology at the University of Maryland.
First, antigens on HIV's surface prompt the immune system to pump out vast quantities of anti-HIV antibodies, which bind to the antigen and even trigger the destruction of some HIV.